Summary of the Conference Call for BaiO SaiTu Company Overview - BaiO SaiTu, established in 2009, is a publicly listed company in Hong Kong and A-shares, headquartered in Beijing with animal production centers in Jiangsu and a research base in Boston, USA [3][4] - The company operates two core business lines: "Model Organisms" and "Thousand Mice and Ten Thousand Antibodies" [3] Financial Performance - In 2025, BaiO SaiTu achieved revenue of 1.378 billion yuan (+41%) and net profit of 173 million yuan (+400%), marking a profitability turning point [2][4] - Operating cash flow reached 370 million yuan (+75%) [2] - The company expects a compound annual growth rate (CAGR) of at least 35% from 2026 to 2028 [2] Business Segments Preclinical Business - Revenue from preclinical services (including animal model sales and CRO services) was approximately 1 billion yuan (+58%) in 2025, with a gross margin of over 70% [4][5] - The growth in pharmacological services was particularly rapid, with the company serving global top 10 pharmaceutical companies [5] Antibody Business - The "Thousand Mice and Ten Thousand Antibodies" business generated 330 million yuan in revenue in 2025, maintaining a gross margin of over 80% [5] - The company anticipates milestone revenue from antibody projects to reach 100 million yuan in 2026, with over 10 molecules expected to enter clinical or IND stages [4][10] Technological Advancements - The RenSuper-AI platform, launched in March 2026, aims to enhance antibody transfer efficiency by 5-20 times through AI predictions and automated wet experiments [2][8] - The company has developed over 1 million high-quality antibody sequences since the initiation of the "Thousand Mice and Ten Thousand Antibodies" program [5][12] Market Dynamics - The demand for model organisms, particularly humanized mice, is expected to grow at a rate of no less than 15% annually, driven by the expansion of application scenarios and the increasing complexity of drug molecules [6][23] - BaiO SaiTu aims to capture over 50% of the global market share in innovative animal models, leveraging its technological advantages and established production systems [22][23] Global Expansion - The company has focused on global expansion, particularly in the U.S. market, where it has maintained a 60% CAGR in overseas business from 2023 to 2025 [7] - Overseas revenue accounted for approximately 70% of total revenue, with significant contributions from top global pharmaceutical companies [7] Capacity Expansion - A new facility in Jiangsu, covering 15,000 square meters, is expected to be operational by Q3 2026, adding 120,000 cage positions (+40%) to meet growing demand [18] - Plans for a new 90,000 to 100,000 square meter facility are underway to support GLP services and global exports by 2028 [18] Cost Management - The company plans to reduce R&D expense ratio from 30% to around 25% while ensuring profit growth outpaces revenue growth [4][19] - Financial expenses are expected to decrease significantly in 2026 [4][19] Future Outlook - BaiO SaiTu's strategic development is divided into two phases: 2020-2024 focused on technology foundation and 2025-2028 aimed at harvesting the results of previous investments [9] - The company anticipates rapid profit release, particularly from milestone payments starting in 2026 [10][24] Conclusion - BaiO SaiTu is positioned to leverage its technological advancements, global market presence, and strategic planning to drive significant growth in the coming years, particularly in the antibody and preclinical service sectors [26][27]

Group 1 - The board of directors of Shanghai Nanfang Model Biological Technology Co., Ltd. held its 24th meeting of the third board on August 28, 2025, with all 9 directors present, including 3 independent directors [1] - The meeting approved several proposals through a voting process, with all votes in favor (9 votes for, 0 against, 0 abstentions) [1][2] - The approved proposals included the 2025 semi-annual report and the special report on the use of raised funds, which were disclosed on the Shanghai Stock Exchange website [1][2] Group 2 - The board also approved a plan for share repurchase and a semi-annual evaluation report on the "Quality Improvement and Efficiency Enhancement Return" action plan, with unanimous support [2]

Group 1 - The company received a request from its controlling shareholder, Shanghai Tishi Enterprise Management Consulting Co., Ltd., to convene an extraordinary general meeting of shareholders to discuss the re-election of the board of directors [1][2] - The request is based on the expiration of the current board's term on May 19, 2025, and aims to ensure proper corporate governance and the company's stable operation [1][2] - The company is required to respond to the request within 10 days, indicating whether it agrees or disagrees to hold the extraordinary general meeting [2] Group 2 - The controlling shareholder holds more than 10% of the company's shares, which allows them to request the meeting under relevant laws and regulations [2] - The extraordinary general meeting is proposed to be held within 30 days from the date of the request [2] - The company will disclose all relevant information in accordance with legal requirements and designated media [2][3]

Core Viewpoint - The announcement details the completion of a share transfer involving major shareholders of Shanghai Nanmo Biological Technology Co., Ltd., with a total of 8,679,727 shares transferred to Suzhou Haiwang Hezhong Equity Investment Partnership, representing a significant change in ownership structure [1][2][3]. Share Transfer Agreement Details - On June 25, 2025, major shareholders including Shenzhen Qianhai Hairun Rongfeng Investment Partnership, Kangjun Investment Management (Beijing) Co., Ltd., and Shanghai Zhangjiang Collective Asset Investment Management Co., Ltd. signed a share transfer agreement to transfer shares to Haiwang Hezhong at a price of 27.369 yuan per share [1][2]. - The shares transferred include 4,650,318 shares from Hairun Rongfeng (5.96% of total shares), 2,247,409 shares from Kangjun Ningyuan (2.88%), and 1,782,000 shares from Zhangjiang Collective (2.29%) [2][3]. Completion of Share Transfer - The share transfer was officially completed on August 11, 2025, with the shares being classified as unrestricted circulating shares [3][4]. - Post-transfer, the shareholding structure shows that Haiwang Hezhong now holds 8,679,727 shares, representing 11.13% of the total shares, while the previous shareholders have reduced their holdings accordingly [4][5]. Shareholding Changes - Following the transfer, the updated shareholding structure indicates that Haiwang Hezhong and its concerted action partner, Shanghai Pudong New Industry Investment Co., Ltd., collectively hold 14,022,795 shares, accounting for 17.99% of the total shares [5]. - The share transfer does not impose any restrictions on the transferred shares, and the shareholders have committed to not reducing their holdings for 12 months following the transfer [5].

Core Viewpoint - The announcement details the upcoming release of 28,575,000 restricted shares of Shanghai Nanfang Model Biology Technology Co., Ltd. for public trading, effective June 30, 2025, following the expiration of the lock-up period [1][2]. Group 1: Stock Listing Details - The total number of shares to be listed is 28,575,000, representing 36.65% of the company's total share capital [2][11]. - The shares are part of the initial public offering (IPO) and were originally subject to a 36-month lock-up period, which has been extended by 6 months due to specific conditions [2][3]. - The new trading date is set for June 30, 2025, as June 28, 2025, is a non-trading day [1][2]. Group 2: Shareholder Commitments - The controlling shareholder, Shanghai Dishi Enterprise Management Consulting Co., Ltd., has made commitments regarding the lock-up and reduction of shareholdings, including a promise not to transfer shares for 36 months post-IPO [3][5]. - If the stock price falls below the IPO price for 20 consecutive trading days within the first 6 months, the lock-up period will automatically extend for at least another 6 months [3][7]. - Other shareholders, including Shanghai Puyu Enterprise Management Consulting Partnership and Shanghai Dajun Enterprise Management Consulting Partnership, have made similar commitments regarding their shares [6][7]. Group 3: Regulatory Compliance - The underwriting institution, Guotai Junan Securities Co., Ltd., has confirmed that the release of restricted shares complies with relevant laws and regulations, ensuring accurate and complete disclosure of information [10]. - The company has not experienced any changes in share capital due to profit distribution or other factors since the formation of the restricted shares [2][10]. Group 4: Current Shareholder Status - As of the announcement date, all shareholders have adhered to their commitments, and there are no outstanding issues affecting the release of the restricted shares [9]. - There are no instances of fund occupation by the controlling shareholder or related parties [9].